Skip to main content

Kalaris Therapeutics, Inc.

KLRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001754068

No open-market purchases or sales by Kalaris Therapeutics, Inc. insiders were filed in the last 90 days; 56 institutions reported holding it in 13F filings for Q2 2026, worth $73.4M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Kalaris Therapeutics, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Kalaris Therapeutics, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Kalaris Therapeutics, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Vandekop Amy O'LearyVP, Corporate Controller–Aug 28, 20261
Keating LaurieDirector–Aug 3, 20261
Bayko Liisa AnnChief Financial Officer–Jul 20, 20261
Patterson Leone DDirector–Jun 4, 20261
Akkaraju SrinivasDirector19,408IndirectJun 4, 20264
Adamis Anthony PDirector–Jun 4, 20261
Hallal DavidDirector2,143,662Jun 4, 20261
Jovan-Embiricos MoranaDirector100,197Jun 4, 20261
Dybbs MichaelDirector–Jun 4, 20261
Ferrara NapoleoneDirector504,000Jun 4, 20261
Samsara BioCapital, L.P.10% Owner19,408IndirectMay 22, 20262
Samsara BioCapital GP, LLC10% Owner19,408IndirectMay 22, 20262
Samsara Opportunity Fund, L.P.10% Owner19,408IndirectMay 22, 20263
Samsara Opportunity Fund GP, LLC10% Owner19,408IndirectMay 22, 20263
Hagen Brett RChief Accounting Officer0Mar 23, 20261
Feinsod MatthewChief Medical Officer4,030Mar 20, 20261
Oxtoby AndrewSee Remarks–Mar 20, 20261
Gall MatthewChief Financial Officer–Mar 20, 20262
Patel Samir ChandrakantDirector100,800IndirectApr 11, 20250
Sinha VikasSee Remarks49,129Feb 24, 20250
Miller EdwardGeneral Counsel6,517Feb 24, 20250
Brainard DianaChief Executive Officer723,363Nov 20, 20240
Bornstein Jeffrey SDirector110,197Jun 7, 20240
Tomasello ShawnDirector70,000Jun 7, 20240
Vera JuanDirector2,409,928Jun 7, 20240
Brenner MalcolmDirector100,197Jun 7, 20240
Adams Derek N.Director70,000Jun 7, 20240
Piccina CintiaChief Commercial Officer147,000Jul 5, 20230
Gilead Sciences, Inc.10% Owner16,635,286Jun 28, 20230
Leen Ann M.Chief Scientific Officer124,006Feb 3, 20230
Van Beek Jeroen BChief Commercial Officer333,726Nov 18, 20220
Atillasoy ErcemSee Remarks131,372Oct 26, 20220
Gadicke AnsbertDirector, 10% Owner16,674,766IndirectAug 1, 20220
ElevateBio, LLCDirector, 10% Owner16,674,766Aug 1, 20220
Melian AgustinChief Medical Officer453,529Oct 5, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
May 19, 2023 (view filing)May 181 dayBrainard DianaChief Executive OfficerSSale−4.54K$4.21−$19.1K−0.5%916.6K after10b5-1
Apr 21, 2023 (view filing)Apr 19-202 daysSinha VikasSee RemarksSSale−2.68K$3.67−$9.84K−0.2%1.19M after2 lots10b5-1
Apr 21, 2023 (view filing)Apr 19-202 daysHagen Brett RChief Accounting OfficerSSale−697$3.67−$2.56K−0.5%134.6K after2 lots10b5-1
Apr 21, 2023 (view filing)Apr 192 daysBrainard DianaChief Executive OfficerSSale−8.41K$3.71−$31.2K−0.9%921.2K after10b5-1
Feb 23, 2023 (view filing)Feb 212 daysBrainard DianaChief Executive OfficerSSale−5.12K$6.63−$34.0K−0.5%929.6K after
Jan 23, 2023 (view filing)Jan 19-204 daysSinha VikasSee RemarksSSale−6.54K$5.09−$33.3K−0.6%1.03M after2 lots
Jan 23, 2023 (view filing)Jan 19-204 daysMiller EdwardGeneral CounselSSale−2.57K$5.09−$13.1K−1.7%148.5K after2 lots
Jan 23, 2023 (view filing)Jan 19-204 daysHagen Brett RChief Accounting OfficerSSale−1.90K$5.09−$9.65K−2.5%74.0K after2 lots
Jan 23, 2023 (view filing)Jan 194 daysBrainard DianaChief Executive OfficerSSale−34.4K$5.08−$174.9K−5.4%601.6K after
Nov 21, 2022 (view filing)Nov 183 daysBrainard DianaChief Executive OfficerSSale−4.51K$7.27−$32.8K−0.7%633.0K after
Nov 18, 2022 (view filing)Nov 162 daysVan Beek Jeroen BChief Commercial OfficerSSale−16.1K$7.50−$120.6K−4.6%333.7K after
Nov 16, 2022 (view filing)Nov 142 daysMiller EdwardGeneral CounselSSale−2.36K$8.91−$21.0K−1.2%190.5K after
Nov 15, 2022 (view filing)Nov 114 daysVan Beek Jeroen BChief Commercial OfficerSSale−36.6K$8.20−$300.1K−9.5%349.8K after
Nov 14, 2022 (view filing)Nov 10-114 daysHagen Brett RChief Accounting OfficerSSale−24.0K$8.14−$195.2K−24.0%75.9K after2 lots
Nov 10, 2022 (view filing)Nov 8-102 daysVan Beek Jeroen BChief Commercial OfficerSSale−13.4K$8.00−$107.3K−3.4%386.4K after2 lots
Oct 26, 2022 (view filing)Oct 206 daysMiller EdwardGeneral CounselSSale−553$9.36−$5.18K−0.2%249.4K afterAmended
Oct 26, 2022 (view filing)Oct 20-216 daysAtillasoy ErcemSee RemarksSSale−2.10K$8.72−$18.3K−1.6%131.4K afterAmended2 lots
Oct 26, 2022 (view filing)Oct 206 daysHagen Brett RChief Accounting OfficerSSale−345$9.36−$3.23K−0.3%113.2K afterAmended
Oct 26, 2022 (view filing)Oct 206 daysVan Beek Jeroen BChief Commercial OfficerSSale−1.07K$9.36−$10.0K−0.3%399.8K afterAmended
Oct 26, 2022 (view filing)Oct 206 daysSinha VikasSee RemarksSSale−1.45K$9.36−$13.6K−0.1%1.04M afterAmended
Oct 24, 2022 (view filing)Oct 21-243 daysHagen Brett RChief Accounting OfficerSSale−13.3K$8.40−$112.0K−11.8%99.9K afterFrom original2 lots
Oct 21, 2022 (view filing)Oct 192 daysHallal DavidDirector, 10% OwnerSSale−600.0K$8.45−$5.07M−81.3%138.2K after
Sep 30, 2022 (view filing)Sep 291 dayHallal DavidDirector, 10% OwnerSSale−400.0K$7.35−$2.94M−35.7%721.0K after
Sep 6, 2022 (view filing)Sep 24 daysVan Beek Jeroen BChief Commercial OfficerSSale−493$7.89−$3.89K−0.1%400.9K after
Aug 19, 2022 (view filing)Aug 181 dayBrainard DianaChief Executive OfficerSSale−4.56K$7.76−$35.4K−0.7%637.5K after
Aug 17, 2022 (view filing)Aug 161 dayVan Beek Jeroen BChief Commercial OfficerSSale−15.6K$8.30−$129.4K−3.9%386.4K after
Jul 22, 2022 (view filing)Jul 211 dayAtillasoy ErcemSee RemarksSSale−1.53K$5.38−$8.25K−1.1%133.5K after
Jul 21, 2022 (view filing)Jul 21Same dayHallal DavidDirector, 10% OwnerSSale−4.23K$5.33−$22.5K−0.2%2.07M after
Jul 21, 2022 (view filing)Jul 201 daySinha VikasSee RemarksSSale−1.43K$5.21−$7.46K−0.2%938.2K after
Jul 21, 2022 (view filing)Jul 201 dayAtillasoy ErcemSee RemarksSSale−563$5.21−$2.93K−0.4%135.0K after
Jul 21, 2022 (view filing)Jul 201 dayVan Beek Jeroen BChief Commercial OfficerSSale−1.06K$5.21−$5.51K−0.3%402.0K after
Jul 6, 2022 (view filing)Jun 333 daysLateVan Beek Jeroen BChief Commercial OfficerSSale−515$3.63−$1.87K−0.1%389.0K after
Jun 6, 2022 (view filing)Jun 33 daysHallal DavidDirector, 10% OwnerSSale−65.7K$3.67−$241.2K−3.1%2.08M after
May 23, 2022 (view filing)May 185 daysLateBrainard DianaChief Executive OfficerSSale−29.1K$4.33−$126.2K−5.6%492.2K after
May 18, 2022 (view filing)May 171 dayVan Beek Jeroen BChief Commercial OfficerSSale−15.3K$4.40−$67.2K−3.8%389.5K after
Apr 28, 2022 (view filing)Apr 262 daysBornstein Jeffrey SDirectorPPurchase+5.00K$4.64+$23.2K+14.2%40.2K after
Apr 22, 2022 (view filing)Apr 211 dayHallal DavidDirector, 10% OwnerSSale−4.23K$5.87−$24.8K−0.2%2.14M after
Apr 22, 2022 (view filing)Apr 202 daysSinha VikasSee RemarksSSale−1.16K$6.68−$7.76K−0.1%906.6K after
Apr 22, 2022 (view filing)Apr 202 daysVan Beek Jeroen BChief Commercial OfficerSSale−852$6.68−$5.69K−0.2%404.8K after
Apr 22, 2022 (view filing)Apr 20-212 daysAtillasoy ErcemSee RemarksSSale−2.04K$6.04−$12.3K−1.7%121.6K after2 lots
Apr 22, 2022 (view filing)Apr 202 daysHagen Brett RChief Accounting OfficerSSale−276$6.68−$1.84K−0.3%80.4K after
Mar 11, 2022 (view filing)Mar 10-111 dayHallal DavidDirector, 10% OwnerSSale−65.7K$7.48−$491.7K−3.0%2.15M after2 lots
Mar 3, 2022 (view filing)Mar 21 dayVan Beek Jeroen BChief Commercial OfficerSSale−516$9.01−$4.65K−0.1%382.4K after
Feb 18, 2022 (view filing)Feb 162 daysVan Beek Jeroen BChief Commercial OfficerSSale−15.3K$8.32−$127.5K−3.8%382.9K after
Feb 10, 2022 (view filing)Feb 10Same dayBornstein Jeffrey SDirectorPPurchase+5.00K$8.87+$44.4K+16.6%35.2K after
Jan 26, 2022 (view filing)Jan 251 dayAtillasoy ErcemSee RemarksSSale−4.64K$8.24−$38.2K−4.4%100.3K after
Jan 25, 2022 (view filing)Jan 241 dayHallal DavidDirector, 10% OwnerSSale−17.1K$8.01−$137.0K−0.8%2.21M after
Jan 24, 2022 (view filing)Jan 204 daysVan Beek Jeroen BChief Commercial OfficerSSale−4.66K$8.75−$40.7K−1.2%398.2K after
Jan 24, 2022 (view filing)Jan 204 daysHagen Brett RChief Accounting OfficerSSale−1.56K$8.75−$13.7K−2.4%63.2K after
Jan 24, 2022 (view filing)Jan 204 daysSinha VikasSee RemarksSSale−6.45K$8.75−$56.4K−0.7%859.0K after